Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

XyloCor Therapeutics, Inc., ("XyloCor"), a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of a $67.5 million Series ...

Researchers have discovered that the protein Hmga1, found in zebrafish, can repair damaged mouse hearts by reactivating ...

“As our understanding of the genetic basis of cardiomyopathies increases, gene therapy emerges as a revolutionary approach ...

Discover promising gene therapy results from Tenaya Therapeutics, Inc.'s TN-201 and TN-401 projects, potential impact on ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several ...

Recent discoveries in genetic editing technologies are paving the way for treatments aimed at correcting genetic mutations that cause various diseases, including rare conditions like progeria. This ...

The data suggests that Hmga1, a key protein for regenerating heart cells, could be a target for gene therapies that prevent cardiac failure.

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease Proceeds of financing will ...